41144 Federal Register / Vol. 74, No. 156 / Friday, August 14, 2009 / Notices 

provided by the International 

Federation of Pharmaceutical 

Manufacturers Associations (IFPMA). 

The ICH Steering Committee includes 

representatives from each of the ICH 

sponsors and the IFPMA, as well as 

observers from the World Health 

Organization, Health Canada, and the 

European Free Trade Area. 

In June 2009, the ICH Steering 

Committee agreed that a draft guidance 

entitled ‘‘Q4B Evaluation and 

Recommendation of Pharmacopoeial 

Texts for Use in the ICH Regions; Annex 

10: Polyacrylamide Gel Electrophoresis 

General Chapter’’ should be made 

available for public comment. The draft 

guidance is the product of the Q4B 

Expert Working Group of the ICH. 

Comments about this draft will be 

considered by FDA and the Q4B Expert 

Working Group. 

The draft guidance provides the 

specific evaluation results from the ICH 

Q4B process for the Polyacrylamide Gel 

Electrophoresis General Chapter 

harmonization proposal originating 

from the three-party PDG. This draft 

guidance is in the form of an annex to 

the core ICH Q4B guidance. Once 

finalized, the annex will provide 

guidance to assist industry and 

regulators in the implementation of the 

specific topic evaluated by the ICH Q4B 

process. 

This draft guidance is being issued 

consistent with FDA’s good guidance 

practices regulation (21 CFR 10.115). 

The draft guidance, when finalized, will 

represent the agency’s current thinking 

on this topic. It does not create or confer 

any rights for or on any person and does 

not operate to bind FDA or the public. 

An alternative approach may be used if 

such approach satisfies the 

requirements of the applicable statutes 

and regulations. 

II. Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic 

comments on the draft guidance. Submit 

a single copy of electronic comments or 

two paper copies of any mailed 

comments, except that individuals may 

submit one paper copy. Comments are 

to be identified with the docket number 

found in brackets in the heading of this 

document. Received comments may be 

seen in the Division of Dockets 

Management between 9 a.m. and 4 p.m., 

Monday through Friday. 

III. Electronic Access 

Persons with access to the Internet 

may obtain the document at http:// 

www.regulations.gov, http:// 

www.fda.gov/Drugs/Guidance

ComplianceRegulatoryInformation/ 

Guidances/default.htm, or http:// 

www.fda.gov/AnimalVeterinary/ 

GuidanceComplianceEnforcement/ 

GuidanceforIndustry/default.htm. 

Dated: July 31, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–19522 Filed 8–13–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–D–0343] 

International Conference on 

Harmonisation; Draft Guidance on Q4B 

Evaluation and Recommendation of 

Pharmacopoeial Texts for Use in the 

International Conference on 

Harmonisation Regions; Annex 9 on 

Tablet Friability General Chapter; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

availability of a draft guidance entitled 

‘‘Q4B Evaluation and Recommendation 

of Pharmacopoeial Texts for Use in the 

ICH Regions; Annex 9: Tablet Friability 

General Chapter.’’ The draft guidance 

was prepared under the auspices of the 

International Conference on 

Harmonisation of Technical 

Requirements for Registration of 

Pharmaceuticals for Human Use (ICH). 

The draft guidance provides the results 

of the ICH Q4B evaluation of the Tablet 

Friability General Chapter harmonized 

text from each of the three 

pharmacopoeias (United States, 

European, and Japanese) represented by 

the Pharmacopoeial Discussion Group 

(PDG). The draft guidance conveys 

recognition of the three pharmacopoeial 

methods by the three ICH regulatory 

regions and provides specific 

information regarding the recognition. 

The draft guidance is intended to 

recognize the interchangeability 

between the local regional 

pharmacopoeias, thus avoiding 

redundant testing in favor of a common 

testing strategy in each regulatory 

region. This draft guidance is the ninth 

annex to the core Q4B guidance, which 

was made available in the Federal 

Register of February 21, 2008 (73 FR 

9575). 

DATES: Although you can comment on 

any guidance at any time (see 21 CFR 

10.115 (g)(5)), to ensure that the agency 

considers your comment on this draft 

guidance before it begins work on the 

final version of the guidance, submit 

written or electronic comments on the 

draft guidance by October 13, 2009. 

ADDRESSES: Submit written requests for 

single copies of the draft guidance to the 

Division of Drug Information (HFD– 

240), Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 51, rm. 2201, Silver Spring, 

MD 20993–0002; or the Office of 

Communication and Development, 

Center for Biologics Evaluation and 

Research, Food and Drug 

Administration, 1401 Rockville Pike, 

suite 200N, Rockville, MD 20852–1448. 

The guidance may also be obtained by 

mail by calling the Center for Biologics 

Evaluation and Research at 1–800–835– 

4709 or 301–827–1800. Send two selfaddressed adhesive labels to assist the 

office in processing your requests. 

Submit written comments on the draft 

guidance to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments to http:// 

www.regulations.gov. See the 

SUPPLEMENTARY INFORMATION section for 

electronic access to the draft guidance 

document. 

FOR FURTHER INFORMATION CONTACT: 

Regarding the guidance: Robert H. 

King, Sr., Center for Drug 

Evaluation and Research (HFD– 

003), Food and Drug 

Administration, 10903 New 

Hampshire Ave., Bldg. 51, rm. 4150, 

Silver Spring, MD 20993–0002, 

301–796–1242; or 

Christopher Joneckis, Center for 

Biologics Evaluation and Research 

(HFM–25), Food and Drug 

Administration, 1401 Rockville 

Pike, suite 200N, Rockville, MD 

20852–1448, 301–827–0373. 

Regarding the ICH: Michelle Limoli, 

Office of International Programs 

(HFG–1), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827– 

4480. 

SUPPLEMENTARY INFORMATION: 

I. Background 

In recent years, many important 

initiatives have been undertaken by 

regulatory authorities and industry 

associations to promote international 

harmonization of regulatory 

requirements. FDA has participated in 

many meetings designed to enhance 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 74, No. 156 / Friday, August 14, 2009 / Notices 41145 

harmonization and is committed to 

seeking scientifically based harmonized 

technical procedures for pharmaceutical 

development. One of the goals of 

harmonization is to identify and then 

reduce differences in technical 

requirements for drug development 

among regulatory agencies. 

ICH was organized to provide an 

opportunity for tripartite harmonization 

initiatives to be developed with input 

from both regulatory and industry 

representatives. FDA also seeks input 

from consumer representatives and 

others. ICH is concerned with 

harmonization of technical 

requirements for the registration of 

pharmaceutical products among three 

regions: The European Union, Japan, 

and the United States. The six ICH 

sponsors are the European Commission; 

the European Federation of 

Pharmaceutical Industries Associations; 

the Japanese Ministry of Health, Labour, 

and Welfare; the Japanese 

Pharmaceutical Manufacturers 

Association; the Centers for Drug 

Evaluation and Research and Biologics 

Evaluation and Research, FDA; and the 

Pharmaceutical Research and 

Manufacturers of America. The ICH 

Secretariat, which coordinates the 

preparation of documentation, is 

provided by the International 

Federation of Pharmaceutical 

Manufacturers Associations (IFPMA). 

The ICH Steering Committee includes 

representatives from each of the ICH 

sponsors and the IFPMA, as well as 

observers from the World Health 

Organization, Health Canada, and the 

European Free Trade Area. 

In June 2009, the ICH Steering 

Committee agreed that a draft guidance 

entitled ‘‘Q4B Evaluation and 

Recommendation of Pharmacopoeial 

Texts for Use in the ICH Regions; Annex 

9: Tablet Friability General Chapter’’ 

should be made available for public 

comment. The draft guidance is the 

product of the Q4B Expert Working 

Group of the ICH. Comments about this 

draft will be considered by FDA and the 

Q4B Expert Working Group. 

The draft guidance provides the 

specific evaluation results from the ICH 

Q4B process for the Tablet Friability 

General Chapter harmonization 

proposal originating from the threeparty PDG. This draft guidance is in the 

form of an annex to the core ICH Q4B 

guidance. Once finalized, the annex will 

provide guidance to assist industry and 

regulators in the implementation of the 

specific topic evaluated by the ICH Q4B 

process. 

This draft guidance is being issued 

consistent with FDA’s good guidance 

practices regulation (21 CFR 10.115). 

The draft guidance, when finalized, will 

represent the agency’s current thinking 

on this topic. It does not create or confer 

any rights for or on any person and does 

not operate to bind FDA or the public. 

An alternative approach may be used if 

such approach satisfies the 

requirements of the applicable statutes 

and regulations. 

II. Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic 

comments on the draft guidance. Submit 

a single copy of electronic comments or 

two paper copies of any mailed 

comments, except that individuals may 

submit one paper copy. Comments are 

to be identified with the docket number 

found in brackets in the heading of this 

document. Received comments may be 

seen in the Division of Dockets 

Management between 9 a.m. and 4 p.m., 

Monday through Friday. 

III. Electronic Access 

Persons with access to the Internet 

may obtain the document at http:// 

www.regulations.gov, http:// 

www.fda.gov/Drugs/Guidance

ComplianceRegulatoryInformation/ 

Guidances/default.htm, or http:// 

www.fda.gov/AnimalVeterinary/ 

GuidanceComplianceEnforcement/ 

GuidanceforIndustry/default.htm. 

Dated: July 31, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–19528 Filed 8–13–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention (CDC) 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Health 

Promotion and Disease Prevention 

Research Centers, Special Interest 

Project Competitive Supplements 

(SIPS) (U48 Panels N–P), RFA–DP09– 

101SUPP09, Initial Review 

Cancellation: The notice was 

originally published in the Federal 

Register on July 21, 2009 (Volume 74, 

Number 138] [page 35877]. The 

following panels are cancelled: N, O and 

P. 

Contact Person for More Information: 

Brenda Colley-Gilbert, Ph.D., Director, 

Extramural Research Program Office, 

CCCH, 4770 Buford Highway, MS K–92, 

Atlanta, GA 30341, Telephone (770) 

488–6295. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–19501 Filed 8–13–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2008–0333] 

Delaware River and Bay Oil Spill 

Advisory Committee; Meeting 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of meeting. 

SUMMARY: The Delaware River and Bay 

Oil Spill Advisory Committee 

(DRBOSAC) will meet in Lewes, DE to 

discuss various issues to improve oil 

spill prevention and response strategies 

for the Delaware River and Bay. This 

meeting will be open to the public. 

DATES: The Committee will meet on 

Wednesday, September 9, 2009, from 2 

p.m. to 4 p.m. This meeting may close 

early if all business is finished. Written 

material, requests to make oral 

presentations, and requests to have a 

copy of your material distributed to 

each member of the committee should 

reach the Coast Guard on or before 

September 2, 2009. 

ADDRESSES: The Committee will meet at 

Virden Retreat Center, University of 

Delaware (the Harbor Room), 700 

Pilottown Road, Lewes, DE 19958. Send 

written material and requests to make 

oral presentations to Gerald Conrad, 

Liaison to the Designated Federal 

Officer (DFO) of the DRBOSAC, Coast 

Guard Sector Delaware Bay, 1 

Washington Ave., Philadelphia, PA 

19147. This notice and any documents 

identified in the Supplementary 

Information section as being available in 

the docket may be viewed online, at 

http://www.regulations.gov, using 

docket number USCG–2008–0333. 

FOR FURTHER INFORMATION CONTACT: 

Gerald Conrad, Liaison to the DFO of 

the DRBOSAC, telephone 215–271– 

4824. 

mstockstill on DSKH9S0YB1PROD with NOTICES